CombinatoRx and Fovea enter into collaboration to develop novel ophthalmic therapeutics built from synergistic drug combinations.

(From Chemical Business NewsBase - Press Release)

CombinatoRx Inc and Fovea Pharmaceuticals SA (Fovea) announced collaboration for the potential development and commercialisation of combination drugs to treat ophthalmic diseases. The agreement unites CombinatoRx's leadership in the systematic discovery of novel combination drug candidates with Fovea's drug development resources and expertise in the field of ophthalmic therapeutics. Under the terms of the agreement, Fovea has agreed to fund and conduct pre-clinical and clinical development of combination drug candidates it selects from the CombinatoRx portfolio, including creating ophthalmic formulations. Fovea has …